VBL Therapeutics

Company Overview

Snapshot

Founded in January 2000 by Dror Harats, VBL Therapeutics operates with 11–50 employees. The company has raised a total of $109.77 million across 5 funding rounds from 8 investors. In February 2023, VBL Therapeutics was acquired by Notable Labs.

Business overview

VBL Therapeutics is a biopharmaceutical company focused on developing targeted therapies for immune-inflammatory diseases and oncology. The company's core technology centers on its Monocyte Targeting Technology (MTT), which includes the investigational monoclonal antibody VB-601. This therapy is designed to specifically block the MOSPD2 ("mono-walk") receptor, limiting the migration of monocytes to inflamed tissues. VBL Therapeutics aims to address a wide range of immune-inflammatory conditions such as multiple sclerosis, rheumatoid arthritis, and non-alcoholic steatohepatitis (NASH), operating within the Health Tech & Life Sciences sector.

Strategic signal

In February 2023, VBL Therapeutics announced a definitive merger agreement with Notable Labs, signaling a significant strategic shift for the company. This acquisition indicates a consolidation within the biopharmaceutical landscape, potentially allowing for combined resources and expertise to advance their respective therapeutic pipelines. For investors, this event highlights the company's transition from an independent entity to being part of a larger organization, which could impact future development and market strategies.

Company Intelligence Q&A

What was a significant recent corporate event for VBL Therapeutics?

In February 2023, VBL Therapeutics announced a definitive merger agreement with Notable Labs, leading to its acquisition.

When did VBL Therapeutics sell its manufacturing facility?

In March 2023, VBL Therapeutics announced the closing of the sale of its manufacturing facility and certain related assets for $7.1 million in cash.

Did VBL Therapeutics receive any significant non-equity funding?

In December 2021, VBL Therapeutics was selected for $17.5 million of funding from the Horizon Europe EIC Accelerator Program.

What was the outcome of the Phase 3 OVAL trial for Ofra-Vec?

In July 2022, VBL Therapeutics announced top-line data from the Phase 3 OVAL trial of Ofra-Vec in patients with platinum-resistant ovarian cancer, which indicated the study failed to meet its primary endpoint.

What strategic action did VBL Therapeutics take in August 2022?

In August 2022, VBL Therapeutics announced a workforce reduction and initiated a corporate process to explore strategic options following the results of the OVAL trial.